Biodesix
Biodesix, Memorial Sloan Kettering Team on Minimal Residual Disease Test
The MRD test will run on the Bio-Rad QX600 ddPCR System, and Biodesix may develop more tests for MSK under the agreement.
Biodesix, Spesana Partner to Improve Workflows for Lung Cancer Molecular Diagnostic Tests
Startup Spesana's digital platform will integrate EMR, lab information, and MDx data to automate clinical workflows, tumor boards, and clinical trial management.
Biodesix, Datavant Join in Lung Cancer Data Partnership
Datavant will anonymize lung cancer records from the Biodesix biobank and add real-world data to aid researchers and biopharma companies.
Biodesix, Addario Lung Cancer Institute Enroll First Patient in NSCLC Biomarker Study
Through the BEACON-Lung study, investigators will use Biodesix's serum-based test to identify predictive biomarkers of immunotherapy response beyond PD-L1.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.